CCR

CCR Related Products (82):

By Effects:	Controls (2) Inhibitors (38) Agonist (1) Antagonists (31) Modulator (1)

Cat. No.	Product Name	Effect	Purity

HY-B0673

Pirfenidone	Inhibitor	99.98%
Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.

HY-B0498

Bindarit	Inhibitor	99.53%
Bindarit (AF2838) is a selective inhibitor of the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8, and no effect on other CC and CXC chemokines such as MIP-1α/CCL3, MIP-1β/CCL4, MIP-3/CCL23. Bindarit also has anti-inflammatory activity.

HY-P3719

MOG(35-55) amide, mouse, rat		99.10%
MOG peptide (35-55) is a fragment 35-55 of myelin oligodendrocyte glycoprotein (MOG) immunogenic peptide. MOG peptide (35-55) is specific to expanded CD4⁺ T?cells, and induces experimental autoimmune encephalomyelitis (EAE) in animal model.

HY-P99188

Carlumab	Inhibitor
Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer.

HY-N2609

7,4'-Dihydroxyflavone	Inhibitor	99.68%
7,4'-Dihydroxyflavone (7,4'-DHF) is a flavonoid, which can be isolated from Glycyrrhiza uralensis. 7,4'-Dihydroxyflavone is eotaxin/CCL11 inhibitor and CBR1 inhibitor (IC₅₀=0.28 μM). 7,4'-Dihydroxyflavone has the ability to consistently suppress eotaxin production and prevent dexamethasone (Dex)‐paradoxical adverse effects on eotaxin production. 7,4'-Dihydroxyflavone (7,4'-DHF) inhibits MUC5AC gene expression, mucus production and secretion via regulation of NF-κB, STAT6 and HDAC2.7,4'-Dihydroxyflavone (7,4'-DHF) decreases phorbol 12-myristate 13-acetate (PMA) stimulated NCI-H292 human airway epithelial cell MUC5AC gene expression and mucus production with IC₅₀ value of 1.4 µM.

HY-112874

BMS-681	Antagonist
BMS-681 is an orthosteric antagonist of CC chemokine receptor 2 (CCR2). BMS-681 restricts the movement of the extracellular end of TM6 by stabilizing TM7. TM7 and TM6 are the main components of the orthosteric binding site. BMS-681 can be used to study inflammatory neurodegenerative diseases and cancer.

HY-P990904

Azirkitug
HY-P990904 is an CCR8-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990914

Denikitug
HY-P990914 is an CCR8-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

HY-116835

BI-6901	Antagonist	99.94%
BI 6901 is a potent, selective CCR10 antagonist (pIC₅₀=9.0). BI 6901 shows high selectivity over other GPCRs, including a number of other chemokine receptors. BI 6901 is efficacious in the murine DNFB model of contact hypersensitivity and can be used for inflammation research.

HY-15545

AZD-4818		99.10%
AZD-4818 is a potent antagonist of chemokine CCR1. AZD-4818 can be used for researching chronic obstructive pulmonary disease (COPD) .

HY-P99697

Leronlimab	Antagonist	98.91%
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer.

HY-156460

CMKLR1 antagonist 1	Antagonist	99.44%
CMKLR1 antagonist 1 (compound S-26d) is a potent and orally active chemokine-like receptor 1 (CMKLR1) antagonist, with a pIC₅₀ value of 7.44 in hCMKLR1-transfected CHO cells. CMKLR1 antagonist 1 can be used for psoriasis and metabolic diseases research.

HY-123763

MLN3126	Antagonist	98.64%
MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC₅₀ value of 6.3 nM for calcium influx.

HY-153670

IPG7236	Antagonist	98.54%
IPG7236 is a selective CCR8 antagonist. IPG7236 exhibits significant tumor suppression in a mouse xenograft model of human breast cancer. IPG7236 can be used in cancer research.

HY-109511

AZD-1678	Antagonist	98.12%
AZD-1678 is a potent CCR4 receptor antagonist, with a pIC₅₀ of 8.6.

HY-B0673R

Pirfenidone (Standard)	Inhibitor
Pirfenidone (Standard) is the analytical standard of Pirfenidone. This product is intended for research and analytical applications. Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.

HY-B0673S

Pirfenidone-d₅	Inhibitor	99.48%
Pirfenidone-d₅ is a deuterium labeled Pirfenidone. Pirfenidone is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities[1][2][3].

HY-148100A

Emapticap pegol sodium	Inhibitor
Emapticap pegol sodium is a inhibitor of pro-inflammatory chemokine C-C motif-ligand 2 (CCL2). Emapticap pegol sodium is a 40-nucleotide oligonucleotide aptamer, displays different Spiegelmers (L-RNA aptamer) isform in human (NOX-E36) and mouse (mNOX-E36).

HY-112792A

(1S)-CCR2 antagonist 1	Antagonist	98.03%
(1S)-CCR2 antagonist 1 is a left-handed chiral body of CCR2 antagonist 1 (HY-112792). CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a K_i of 2.4 nM.

HY-P990297

Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5)	Inhibitor
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is a Armenian hamster-derived IgG, κ type antibody inhibitor, targeting to mouse/rat/human CCL2/MCP-1.

Name
Email *

	Sorry, but the email address you supplied was invalid.